gotistobart (ONC-392)
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Loading color scheme
From novel biology to clinical stage products.
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Our team brings success from biotech pharma, and academia to OncoC4.
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cells Anti-tumor T cells, NK cells and macrophages can be rejuvenated within the tumor microenvironment following ONC-841 treatment Preliminary Phase 1 data on safety, pharmacokinetics, and…
Wakelee is a world-renowned expert in the research and treatment of lung cancer OncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and immunotherapy ROCKVILLE, Maryland, USA, April 2, 2024 — OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer, today…
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with metastatic castration resistant prostate cancer (“mCRPC”) who have progressed on an androgen receptor (“AR”) pathway inhibitor. The trial is expected to enroll 144 patients…